Armando A.
- Country
- France
- Department
- Médecine digestive et hépatobiliaire
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa in Adults with Biopsy‑Confirmed F2–F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa Safety and Tolerability in Adults with F2‑F3 Metabolic Dysfunction‑Associated Steatohepatitis
- PRODIGE 81-FFCD 2101-TRIPLET: Randomized, open-label, phase II-III study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy
Data & Insights
Has run more than one trial at 162 of 305 partner sites.
Specializations
Liver Disease Management
This investigator specializes in treating various forms of liver cirrhosis and its complications, with particular expertise in managing portal hypertension and hepatic encephalopathy. Their research explores therapeutic interventions using medications like carvedilol for cirrhosis-related complications.
- Cirrhotic Portal Hypertension
- Hepatic Encephalopathy Prevention
- Cirrhosis Decompensation Management
Cholangitic Conditions
The investigator focuses on innovative treatments for primary biliary cholangitis and primary sclerosing cholangitis. Their work includes evaluation of bezafibrate therapy in combination with ursodeoxycholic acid for cholestatic liver diseases.
- Cholestatic Liver Disease
- Biliary Tract Disorders
- Therapeutic Drug Combinations
Hepatic Oncology
Specializing in hepatocellular carcinoma treatment, the investigator studies advanced therapeutic approaches including immunotherapy combinations and targeted treatments. Their research encompasses both intermediate and advanced stage liver cancer interventions.
- Liver Cancer Immunotherapy
- Targeted Cancer Treatments
- Chemoembolization Procedures
Metabolic Liver Disease
The investigator conducts research in non-alcoholic steatohepatitis (NASH) and its progression to cirrhosis. Their work includes evaluation of novel therapeutic agents for treating fatty liver disease and its complications.
- NASH Treatment Development
- Liver Fibrosis Management
- Metabolic Liver Disorders
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.